Drug Trial Radar · NCT04783090
MT1013 Clinical TRIAL In Healthy Subject
Last checked: Nov 19, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 28, 2021
Primary completion
Dec 31, 2021
Study completion Mar 17, 2022
Sponsor
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- WCCT Global
- First posted
- Mar 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single ascending dose administration phase one clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of MT1013 injection in healthy subjects.
Conditions
- Healthy Volunteer
Interventions
MT1013Drug
bispecific peptide as a CaSR agonist and a functional OGP analogue
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of MT1013 for injection in healthy adult subjects.Time frame: Three months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WCCT Global, Inc.
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.